Navigation Links
Isis Reports Phase 2 Data on ISIS-APOCIII Rx Showing Substantial Reductions of Triglycerides and Apoc-III in Patients with Familial Chylomicronemia
Date:9/21/2013

60;

"Our focus is to bring ISIS-APOCIIIRx to the market for patients with severely elevated triglycerides.  These patients cannot reduce their triglycerides to safe levels with currently available medicines. We are extremely pleased with the performance of ISIS-APOCIIIRx to date. These data presented today are particularly encouraging as we plan to pursue FCS as the initial indication for ISIS-APOCIIIRx in advance of our next indication in patients with severely elevated triglycerides. We believe that the significant unmet medical need for an effective triglyceride-lowering drug for patients with FCS and the robust, consistent effects we observe with ISIS-APOCIIIRx should enable us to rapidly move forward," said Richard Geary, Ph.D., senior vice president of development at Isis.  "We look forward to discussing our Phase 3 plans with regulators and moving into a Phase 3 program next year in both patients with FCS and patients with severely high triglycerides."

FCS is a rare genetic disorder that affects approximately one to two out of a million people.  The most common genetic cause of FCS is a defect in the lipoprotein lipase (LPL) gene, which results in extremely low levels of LPL activity and a significant reduction in the breakdown of triglycerides from the blood.  In the study reported today, all three patients had the same genetic defect (P207L mutation) resulting in undetectable LPL activity.

ISIS-APOCIIIRx is an antisense drug being developed for the treatment of treat patients with severely high triglycerides either as a single agent or in combination with other triglyceride-lowering agents.  ISIS-APOCIIIRx targets apoC-III, a protein produced by the liver that plays a central role in the regulation of serum triglycerides.  This approach is validated by the fact that humans who produce low levels of apoC-III have
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
2. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
3. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
4. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
5. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
6. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
7. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
8. Luminex Corporation Reports First Quarter 2012 Results
9. Hospira Reports First-Quarter 2012 Results
10. Endo Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA® ER And Voltaren® Gel
11. The Female Health Company Reports Second Quarter Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... ( http://www.researchandmarkets.com/research/vzhr6h/video ) has announced the addition of ... Growth, Trends and Forecast 2014 - 2020" report to ... of fascination since the era of the cold war between ... Russia. Earlier even a small glimpse of human form was ...
(Date:1/23/2015)... analysis of Centers for Medicare and Medicaid Services, (CMS) ... percent of seniors chose lower-cost preferred pharmacy plans that ... The findings were released by Drug Channels . ... of Medicare Part D," said Pharmaceutical Care Management Association ...
(Date:1/23/2015)... DUBLIN , Jan. 23, 2015  Immune Therapeutics, Inc. ... Biotechnology, Inc. for the compounding, packaging and distributing of its ... the United States . ... of compounding naltrexone tablets in various strengths for individual patients ...
Breaking Medicine Technology:Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4
... 2012  The use of an injectable, clot-preventing drug known ... advanced cancer complicated by blood clots increased steadily between ... in The Oncologist , funded by the National ... despite previous research indicating LMWH is the preferred first-line ...
... 2012  MolecularHealth, Inc., a leader in clinico-molecular informatics™, ... collaboration agreement with the U.S. Food and Drug ... Molecular Analysis of Side Effects (MASE), a ... assessment and prediction. The FDA,s Center ...
Cached Medicine Technology:Injectable Treatment for Blood Clots in Advanced Cancer Patients Increases, According to New Research 2Injectable Treatment for Blood Clots in Advanced Cancer Patients Increases, According to New Research 3MolecularHealth and FDA to Collaborate on Analytical Tools for Mechanism-Based Drug Safety Assessment 2
(Date:1/22/2015)... 22, 2015 Padre Murphy's and Owner Tom ... Pro Player Health Alliance (PPHA). The PPHA's passion ... getting everyone, including NFL greats, treated for obstructive sleep apnea ... groups supporting the cause in the valley. The most recent ...
(Date:1/22/2015)... January 23, 2015 Angelweddingdress is a famous ... invites its customers to follow it on Facebook, Twitter, and ... Valentine’s Day gift. Angelweddingdress draws a lottery every week. , ... to Feb. 28, 2015. Click Angelweddingdress homepage for ...
(Date:1/22/2015)... York (PRWEB) January 22, 2015 The federal ... in the U.S. District Court, Southern District of West Virginia ... Inc. in that proceeding’s first bellwether trial. In an Order ... a new trial after finding that C.R. Bard had not ...
(Date:1/22/2015)... 2015 Thousand of GranuFlo lawsuits ( ... its GranuFlo and NaturaLyte dialysis concentrates continue to move ... District Court, District of Massachusetts, Bernstein Liebhard LLP reports. ... has remanded a case filed by the state of ...
(Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post presenting ... . , Purchasing an accidental death and dismemberment rider ... type of rider provides benefits if the insured dies in ... lesser form of life insurance. , AD&D is not ...
Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2
... , , Program ... , , WASHINGTON, Sept. 1 With worries ... The National Education Association Health Information Network (NEA HIN) and The Clorox ... Starting September 2 through September 5, 2009, teachers nationwide can visit ...
... , , , PITTSBURGH, Sept. ... Press Club will welcome co-founder and former president of the renowned ... of Retired Persons (AARP) and Pittsburgh native William (Bill) D. Novelli. ... active as we get older, how to accomplish this, and what ...
... , , ELM GROVE, Wis., Sept. ... their efforts to prevent child abuse. During the month ... developed to raise awareness of the devastating effects of abuse and ... children suffer and more than two thousand die at the ...
... , , , ... Group, Inc. and M. Beacon Enterprises, LLC today announced ... services. Combining Approach Group,s healthcare and IT, and M. ... two companies now offer solutions that meet the urgent ...
... , , HOUSTON, Sept. ... is the first hospital in Houston to feature the CyberKnife((R)), ... non-cancerous tumors. , , The CyberKnife((R)) is the ... beams of high-dose radiation with extreme accuracy throughout the body, including the ...
... WELLESLEY HILLS, Mass., Sept. 1 Joseph F. Finn, ... Development Candidate Program will be part of the intellectual property ... , , The P2Y2, an Early Development ... treatment of constipation. , , The intellectual ...
Cached Medicine News:Health News:National Education Association Health Information Network (NEA HIN) and The Clorox Company Offer Free Disinfecting Wipes to Teachers Nationwide 2Health News:National Education Association Health Information Network (NEA HIN) and The Clorox Company Offer Free Disinfecting Wipes to Teachers Nationwide 3Health News:Compirion Joins the Fight Against Child Abuse 2Health News:Approach Group, Inc. and M. Beacon Enterprises, LLC Announce Strategic Partnership to Provide End-to-End Business Continuity Planning 2Health News:St. Luke's Episcopal Hospital First in Houston to Offer Revolutionary Noninvasive Tumor Treatment 2Health News:St. Luke's Episcopal Hospital First in Houston to Offer Revolutionary Noninvasive Tumor Treatment 3Health News:EPIX Pharmaceuticals, Inc. Announces the P2Y2 Gastrointestinal Early Development Candidate Program Will Be Part of the Intellectual Property Offered For Sale at the September 30, 2009 Auction 2
ThermalSeal RT (2mil) is Optically Clear for Real Time PCR and easy to apply. Works for all plates....
DMSO-resistant microplate sealing film...
Sealing tape, white Rayon, breathable, NS...
Sealing tape, slightly stiffer than Polyolefin tape. Certified RNase and DNase free....
Medicine Products: